The most important thing Oman patients need to understand about cancer treatment in India is that a single doctor does not choose the recommended therapy alone. A multidisciplinary tumour board, including medical, surgical, and radiation oncologists, along with radiologists, pathologists, and, in complex cases, genetic and palliative care specialists, reviews each case and produces a consensus recommendation based on the cancer type, its stage, its molecular profile, and the patient's overall health. This board-based approach is the institutional foundation of cancer care at India's leading NABH and JCI-accredited oncology centres, and it is one of the most clinically significant differences between cancer treatment in India's top oncology hospitals and what most Oman patients can access domestically.
This guide explains how cancer therapies in India are selected based on cancer type and what Oman patients can expect at each stage of the decision process.
The Multidisciplinary Tumour Board: Where Every Treatment Decision Begins
Every cancer treatment decision at India's top oncology centres is built on a single structural foundation. The tumour board examines referred cases jointly and decides the best suitable line of treatment for each patient.
This is not a formality. The tumour board integrates perspectives that no single specialist can provide. The surgical oncologist sees the tumour through the lens of resectability and margin status. The medical oncologist sees it through the lens of systemic disease control and molecular targets. The radiation oncologist sees it through the lens of local control and critical structure sparing. The radiologist reviews the imaging for disease extent. The pathologist reviews the tissue diagnosis for histology, grade, and molecular markers. Their combined output is a treatment plan that no individual specialist could have produced alone.
For Oman patients traveling to India for cancer treatment, the tumour board review is what they should specifically request confirmation of before committing to any centre.
Why the Tumour Board Matters for Oman Patients
For patients who have received a cancer diagnosis in Oman without access to a formal multidisciplinary tumour board review, the Indian tumour board review may itself produce a meaningfully different treatment recommendation. Cases that were classified as inoperable may be reclassified as resectable after surgical oncology input. Cases recommended for immediate surgery may be reclassified as candidates for neoadjuvant chemotherapy followed by surgery, producing better long-term outcomes. Rarer tumour types may require molecular profiling before the correct treatment can be identified. India's tumour board gives every Oman patient's case the clinical breadth of assessment it deserves.
How Treatment Is Selected by Cancer Type
The cancer type is the primary determinant of which therapy modalities are considered, combined, or sequenced. Depending on the cancer type, stage, molecular profile, and overall health, treatment may involve surgery, radiotherapy, chemotherapy, hormone therapy, targeted therapy, immunotherapy, stem cell transplant, and supportive or palliative care. Here is how this framework applies across the major cancer types most commonly presenting in Oman patients.
Breast Cancer
Breast cancer treatment selection in India is among the most molecularly personalised of all cancer types, driven by three biological subtypes that require completely different treatment approaches.
The three receptor status categories that define breast cancer therapy are:
Hormone Receptor Positive (HR+), HER2-Negative
The most common breast cancer subtype. Endocrine therapy with tamoxifen or aromatase inhibitors forms the backbone of treatment, combined with CDK4/6 inhibitors for metastatic disease. Surgery either breast-conserving lumpectomy or mastectomy based on tumour size and patient preference is the local treatment. Radiation follows breast-conserving surgery. Chemotherapy is added for high-risk cases based on genomic profiling tools like Oncotype DX, which predict the benefit of chemotherapy in the HR+ HER2-negative population.
HER2-Positive
Anti-HER2 targeted agents including trastuzumab and pertuzumab are added to chemotherapy for all HER2-positive breast cancers, producing dramatically improved outcomes over chemotherapy alone. Neoadjuvant trastuzumab plus pertuzumab plus chemotherapy followed by surgery is the standard for early-stage HER2-positive disease at India's leading cancer centres. TDM-1 (trastuzumab emtansine) for patients with residual disease after neoadjuvant treatment and tucatinib combinations for metastatic HER2-positive disease are available at Apollo Cancer Centre Chennai and other National Cancer Grid-affiliated centres.
Triple-Negative Breast Cancer (TNBC)
TNBC has no hormonal or HER2 targets, making chemotherapy the backbone of systemic treatment. For PD-L1-positive TNBC, pembrolizumab plus chemotherapy is now standard for metastatic disease following the KEYNOTE-355 trial results. For BRCA-mutated TNBC, PARP inhibitors (olaparib, talazoparib) are targeted options. India's leading oncology centres have access to all these agents.
Lung Cancer
Lung cancer therapy selection in India begins with one of the most critical molecular profiling requirements in all of oncology.
Identifying the Molecular Driver First
Before any treatment is selected for non-small cell lung cancer (NSCLC), the tumour tissue or circulating tumour DNA in blood must be tested for actionable mutations. EGFR mutation is found in approximately 40 to 50 percent of Indian and South Asian NSCLC patients, substantially higher than Western populations. ALK, ROS1, BRAF, MET, RET, NTRK, and KRAS mutations are each targetable with specific approved agents.
EGFR-Positive NSCLC
EGFR-targeted therapy with osimertinib (third-generation EGFR inhibitor) is the standard first-line treatment for EGFR-mutant NSCLC. Extending median survival to five years or more in some series, osimertinib has transformed the prognosis of EGFR-positive lung cancer from a disease measured in months to one measured in years. EGFR-targeted therapy extending median survival to 5+ years is available at India's leading lung cancer centres. Osimertinib is available in India through domestic generic manufacturing at costs significantly below Western pricing.
PD-L1-Positive NSCLC Without Actionable Mutation
For NSCLC without an actionable driver mutation, PD-L1 expression tested by immunohistochemistry guides immunotherapy selection. High PD-L1 expression (TPS above 50 percent) supports first-line pembrolizumab monotherapy. Intermediate and low PD-L1 expression supports pembrolizumab combined with platinum-based chemotherapy.
Small Cell Lung Cancer
Small cell lung cancer is treated with platinum-etoposide chemotherapy plus atezolizumab or durvalumab immunotherapy as standard first-line treatment for extensive-stage disease. Thoracic radiation is added for limited-stage SCLC. Prophylactic cranial irradiation is considered in responders.
Colorectal Cancer
Colorectal cancer therapy selection in India follows a surgical-first pathway modified by molecular profiling findings.
The RAS and MSI Status That Changes Everything
RAS mutation testing (KRAS and NRAS) determines whether anti-EGFR antibodies (cetuximab, panitumumab) can be added to chemotherapy in metastatic disease. RAS-mutant tumours do not respond to anti-EGFR therapy. RAS wildtype tumours benefit significantly. MSI-high (microsatellite instability high) or dMMR (deficient mismatch repair) colorectal cancer responds dramatically to pembrolizumab immunotherapy in the first-line metastatic setting, producing response rates and progression-free survival far superior to chemotherapy alone.
The Rectal Cancer Neoadjuvant Decision
For locally advanced rectal cancer, neoadjuvant concurrent chemoradiotherapy followed by total mesorectal excision (TME) surgery is the evidence-based standard of care. In patients with MSI-high rectal cancer, neoadjuvant pembrolizumab produces pathological complete response in the majority of patients, potentially allowing surgery to be avoided entirely in complete responders — a paradigm currently being adopted at India's leading colorectal oncology programmes.
Prostate Cancer
Prostate cancer treatment selection in India is guided by risk stratification at presentation low, intermediate, high-risk, and metastatic with very different therapy implications for each category.
Localised Disease Treatment Options
For low-risk localised prostate cancer, active surveillance avoiding immediate treatment is appropriate for selected patients. For intermediate and high-risk localised disease, radical prostatectomy or definitive radiotherapy produce equivalent long-term oncological outcomes, with the choice based on patient preference and surgical risk factors. Robotic radical prostatectomy with nerve-sparing techniques is available at India's leading uro-oncology centres, as is high-dose-rate brachytherapy and stereotactic body radiotherapy (SBRT) with five-fraction prostate treatment.
Hormone-Sensitive Metastatic Prostate Cancer
Androgen deprivation therapy (ADT) combined with docetaxel chemotherapy, or ADT combined with an androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide), is standard for metastatic hormone-sensitive disease. Next-generation imaging with PSMA PET/CT, available at India's leading nuclear medicine centres, identifies disease extent that conventional CT and bone scan miss, directly influencing treatment selection.
Gynaecological Cancers
Cervical Cancer
Cervical cancer remains one of the most prevalent cancers in South Asian and Gulf region women. Locally advanced cervical cancer is treated with concurrent cisplatin chemoradiotherapy followed by brachytherapy, which is the international standard of care. Pembrolizumab has been added to concurrent chemoradiotherapy for high-risk locally advanced disease based on the KEYNOTE-A18 trial, a 2024 practice-changing development available at India's National Cancer Grid-affiliated centres. Bevacizumab plus platinum chemotherapy is standard for recurrent or metastatic cervical cancer. PD-L1 testing guides pembrolizumab addition in the first-line metastatic setting.
Ovarian Cancer
Ovarian cancer treatment combines surgical debulking ideally achieving no visible residual disease with platinum-taxane chemotherapy. BRCA1 and BRCA2 testing guides maintenance therapy with PARP inhibitors (olaparib, niraparib) after response to platinum chemotherapy, producing significant improvement in progression-free survival. Homologous recombination deficiency (HRD) testing beyond BRCA further identifies patients who benefit from PARP inhibition.
Head and Neck Cancers
Head and neck squamous cell carcinoma (HNSCC) therapy is among the most technically demanding in oncology, requiring precise coordination between surgical, radiation, and medical oncology.
How the Primary Site Determines Treatment
The primary site within the head and neck region is the most important determinant of which modality is preferred. Laryngeal cancers are treated with radiation-based approaches wherever possible to preserve voice function, with surgery reserved for non-responders. Oral cavity cancers are treated with surgery as the primary modality, with radiation added post-operatively based on pathological risk factors. Oropharyngeal cancers, particularly HPV-associated tumours, have a distinct molecular biology, better prognosis, and ongoing clinical trials exploring de-escalation of treatment intensity.
Cetuximab and Immunotherapy for Advanced HNSCC
For locally advanced HNSCC, concurrent cisplatin chemoradiation is standard. When cisplatin is contraindicated, cetuximab (EGFR antibody) combined with radiation is the alternative. For recurrent and metastatic HNSCC, pembrolizumab monotherapy for PD-L1-positive tumours and pembrolizumab plus chemotherapy regardless of PD-L1 are first-line options, replacing platinum-5FU-cetuximab as the standard for most patients. India's leading head and neck oncology programmes prescribe these agents within guideline-concordant protocols.
Top 5 Oncology Hospitals in India for Oman Patients
Choosing the right hospital requires finding an institution that excels in your specific cancer type and maintains an active multidisciplinary tumour board. India’s premier oncology hospitals combine international accreditation (JCI and NABH), advanced molecular laboratories, cutting-edge surgical platforms, and dedicated international patient services to ensure seamless cross-border care. Here are five leading oncology centres in India frequently chosen by international patients:
Apollo Proton Cancer Centre (APCC), Chennai
South Asia’s first and only proton therapy centre, APCC Chennai is a world-renowned destination for organ-preserving and pediatric oncology. Its pencil-beam proton radiation technology targets tumours with sub-millimeter precision, sparing adjacent vital structures in brain, skull-base, spinal cord, and pediatric cancers. APCC operates comprehensive organ-specific tumour boards and advanced genomic profiling suites.
Fortis Memorial Research Institute (FMRI), Gurgaon (Delhi-NCR)
Recognized for its high-volume surgical oncology program, Fortis Memorial Research Institute (FMRI) combines state-of-the-art robotic surgery suites (da Vinci Xi platform) with advanced medical oncology and bone marrow transplant units. The hospital is particularly well suited for complex gastrointestinal, thoracic, and head-and-neck cancer resections requiring microvascular reconstruction and multi-specialty surgical teams.
HCG Cancer Centre, Bangalore
As one of India's largest dedicated cancer hospital networks, HCG Cancer Centre, Bangalore focuses exclusively on oncology care and precision medicine. It houses advanced genomics and Next-Generation Sequencing (NGS) facilities that fast-track molecular profiling for targeted therapies and immunotherapies. The centre is also a pioneer in CyberKnife radiosurgery and adaptive radiation protocols.
Max Super Speciality Hospital, Saket, New Delhi
Max Saket is an internationally accredited quaternary care facility renowned for its medical oncology division and extensive clinical experience administering advanced immunotherapies, monoclonal antibodies, and targeted inhibitors. Located near the international airport in New Delhi, it offers a dedicated international patient wing, accelerated tumour board scheduling, and comprehensive inpatient palliative and supportive care infrastructure.
Aster Medcity, Kochi (Kerala)
Located within close direct flight connectivity from Muscat to Cochin International Airport, Aster Medcity offers quaternary-level cancer care in an infection-controlled environment. Its Centre of Excellence in Oncology features robotic onco-surgery, a specialized Bone Marrow Transplant unit, advanced nuclear medicine (PET-CT), and disease-specific multidisciplinary teams managing breast, GI, and thoracic malignancies.
Advanced Cancer Technologies Available in India for Oman Patients
The therapy selection process at India's leading centres is supported by a technology infrastructure that directly enables the molecular personalisation of treatment.
Next-Generation Sequencing and Genomic Profiling
Comprehensive genomic profiling by next-generation sequencing identifies actionable mutations across hundreds of cancer-relevant genes simultaneously, finding targetable alterations missed by single-gene sequential testing. India's major academic cancer centres including Apollo Cancer Centre Chennai (National Cancer Grid-affiliated) and AIIMS Delhi perform comprehensive NGS panels on tumour tissue or liquid biopsy. This profiling is what enables the selection of the correct targeted agent osimertinib for EGFR-mutant lung cancer, olaparib for BRCA-mutant breast or ovarian cancer, entrectinib for NTRK-fusion cancer rather than defaulting to less effective chemotherapy.
CAR-T Cell Therapy
CAR-T cell therapy, which engineers the patient's own T-cells to recognise and attack cancer cells, is available at select advanced oncology centres in India including Apollo Proton Cancer Centre. For relapsed or refractory B-cell lymphoma and multiple myeloma, CAR-T represents a potentially curative option for patients who have failed conventional treatment.
Proton Therapy
Apollo Proton Cancer Centre, Chennai, is the only proton therapy facility in South Asia and the Middle East, having treated patients from 147 countries. Proton therapy delivers the radiation dose to the tumour with minimal exit dose to surrounding healthy tissue, producing significant advantages for paediatric cancers, skull base tumours, and cancers adjacent to the spinal cord, heart, or optic structures.
Cost of Cancer Therapies in India for Oman Patients
| Treatment | India cost (approximate) | USA equivalent |
|---|---|---|
| Tumour board consultation and molecular profiling (NGS) | Rs. 25,000 to Rs. 60,000 (USD 300 to USD 720) | USD 3,000 to USD 8,000 |
| Surgical oncology (major resection) | Rs. 2,00,000 to Rs. 6,00,000 (USD 2,400 to USD 7,200) | USD 40,000 to USD 100,000 |
| Chemotherapy per cycle | Rs. 15,00,0 to Rs. 80,000 (USD 180 to USD 960) | USD 5,000 to USD 20,000 |
| EGFR targeted therapy (osimertinib, per month) | Rs. 25,000 to Rs. 60,000 (USD 300 to USD 720) | USD 8,000 to USD 12,000 |
| Pembrolizumab immunotherapy per cycle | Rs. 80,000 to Rs. 1,50,000 (USD 960 to USD 1,800) | USD 10,000 to USD 20,000 |
| Radiation therapy full course (IMRT or VMAT) | Rs. 1,50,000 to Rs. 3,00,000 (USD 1,800 to USD 3,600) | USD 30,000 to USD 80,000 |
| Proton therapy full course | Rs. 8,00,000 to Rs. 20,00,000 (USD 9,600 to USD 24,000) | USD 60,000 to USD 150,000 |
All figures represent savings of 60 to 90 percent versus the USA, using equivalent technology and guideline-concordant protocols at NABH and JCI-accredited centres.
How Karetrip Connects Oman Patients to the Right Cancer Centre in India
The cancer centre that is best for one Oman patient's breast cancer is not automatically best for another patient's lung cancer or colorectal cancer. Karetrip reviews each patient's pathology report, staging scans, and molecular profiling results before recommending an Indian cancer centre, confirming the proposed programme has the specific oncology subspecialty depth, molecular profiling capability, and treatment technology that the patient's cancer type and stage require. From pre-travel record review and medical visa coordination for the patient and accompanying family, through tumour board scheduling, accommodation near the treating centre, in-hospital coordination, and post-treatment discharge documentation for continuation of therapy in Oman, Karetrip manages the complete international patient journey.
Chat with our Medical care assistant, RUA, for quick guidance and support and take the first step toward a cancer treatment plan selected by the full multidisciplinary team at India's leading oncology centres.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Cancer treatment selection requires evaluation by a qualified oncologist and a multidisciplinary tumour board. All treatment decisions must be made by your treating specialist team based on your individual diagnosis and staging.